NYSE:NHWK NightHawk Biosciences - NHWK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NightHawk Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.93 +0.03 (+2.89%) (As of 03/20/2023 02:34 PM ET) Add Compare Share Share Today's Range$0.88▼$0.9450-Day Range$0.88▼$1.2452-Week Range$0.75▼$3.42Volume26,610 shsAverage Volume43,356 shsMarket Capitalization$23.76 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media NightHawk Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.0% Downside$0.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.36) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.38 out of 5 starsMedical Sector983rd out of 983 stocksPharmaceutical Preparations Industry480th out of 480 stocks 0.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $0.00, NightHawk Biosciences has a forecasted downside of 100.0% from its current price of $0.93.Amount of Analyst CoverageNightHawk Biosciences has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NHWK. Previous Next 0.0 Dividend Strength Dividend YieldNightHawk Biosciences does not currently pay a dividend.Dividend GrowthNightHawk Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NHWK. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 6 people have searched for NHWK on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added NightHawk Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NightHawk Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of NightHawk Biosciences is held by insiders.Percentage Held by InstitutionsOnly 9.52% of the stock of NightHawk Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NightHawk Biosciences are expected to grow in the coming year, from ($1.36) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NightHawk Biosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NightHawk Biosciences is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNightHawk Biosciences has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NightHawk Biosciences (NYSE:NHWK) StockNightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.Read More Receive NHWK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NHWK Stock News HeadlinesDecember 12, 2022 | finance.yahoo.comNHWK: Shifting Focus to BiomanufacturingNovember 15, 2022 | finance.yahoo.comNightHawk Biosciences Provides Third Quarter 2022 Business UpdateMarch 20, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. October 25, 2022 | bizjournals.comNew VelocityTX biomanufacturer increases jobs target as new production facility nears completionOctober 21, 2022 | technews.tmcnet.comNighthawk Biosciences' Scorpion Subsidiary Announces Grand Opening of its San Antonio FacilityOctober 21, 2022 | finance.yahoo.comNighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio FacilityOctober 14, 2022 | reuters.comNightHawk Biosciences IncAugust 24, 2022 | bizjournals.comMorrisville drugmaker building biosafety facility as part of strategy shiftMarch 20, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.August 23, 2022 | finance.yahoo.comNightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) LaboratoryAugust 17, 2022 | finance.yahoo.comNHWK: Scorpion Grand Opening 3Q:22August 10, 2022 | finance.yahoo.comNightHawk Biosciences Provides Second Quarter 2022 Business UpdateJuly 7, 2022 | benzinga.comNightHawk Biosciences (AMEX:NHWK), Analyst Ratings, Price Targets, PredictionsJune 15, 2022 | thestreet.comNightHawk Biosciences Inc.June 14, 2022 | seekingalpha.comNHWK NightHawk Biosciences, Inc.June 13, 2022 | finance.yahoo.comNightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological ServicesJune 13, 2022 | finance.yahoo.comNightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological ServicesJune 5, 2022 | nasdaq.comNightHawk Biosciences, Inc. Common Stock (NHWK)May 18, 2022 | finance.yahoo.comNHWK: Name Change and New FacilityMay 16, 2022 | seekingalpha.comNightHawk Biosciences GAAP EPS of -$0.32 beats by $0.17May 16, 2022 | finance.yahoo.comNightHawk Biosciences Provides First Quarter 2022 Business UpdateMay 14, 2022 | investing.comNighthawk Biosciences Inc (NHWK)May 3, 2022 | seekingalpha.comHeat Biologics completes name change to NightHawk BiosciencesMay 3, 2022 | finance.yahoo.comHeat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open TodayApril 27, 2022 | finance.yahoo.comMorrisville drugmaker scores $6M deal with Canada for anthrax treatmentApril 27, 2022 | seekingalpha.comHeat Biologics stock soars 9% on supply contract with Canada for anthrax drug AnthimApril 27, 2022 | finance.yahoo.comHeat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian GovernmentSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NHWK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NHWK Company Calendar Last Earnings11/09/2021Today3/20/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NHWK CUSIPN/A CIK1476963 Webwww.nighthawkbio.com PhoneN/AFaxN/AEmployees39Year Founded2008Price Target and Rating Average Stock Price Forecast$0.00 High Stock Price Forecast$0.00 Low Stock Price Forecast$10,000,000.00 Forecasted Upside/Downside+788.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($1.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,070,000.00 Net Margins-648.44% Pretax Margin-658.18% Return on Equity-45.24% Return on Assets-36.70% Debt Debt-to-Equity Ratio0.08 Current Ratio4.60 Quick Ratio4.60 Sales & Book Value Annual Sales$2.11 million Price / Sales10.95 Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book0.20Miscellaneous Outstanding Shares25,660,000Free Float23,326,000Market Cap$23.09 million OptionableNot Optionable Beta0.57 Social Links Key ExecutivesMr. Jeffrey Alan Wolf J.D. (Age 60)Founder, Chairman, CEO & Pres Comp: $1.31MMr. William L. Ostrander (Age 55)CFO & Sec. Comp: $371.07kDr. Justin Stebbing FRCPFRCPath, M.A., M.D., Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardColonel George E. Peoples Jr.F.A.C.S., FACS, M.D., Chief Medical AdvisorDr. Anthony M. Manning Ph.D. (Age 61)Chief Scientific Advisor Dr. Paul W. Tebbey M.B.A.Ph.D., Sr. VP of Product Devel. & Portfolio StrategyMore ExecutivesKey CompetitorsBiora TherapeuticsNASDAQ:BIORImpel PharmaceuticalsNASDAQ:IMPLAgeX TherapeuticsNYSE:AGECyclerion TherapeuticsNASDAQ:CYCNMetacrineNASDAQ:MTCRView All CompetitorsInstitutional OwnershipMillennium Management LLCBought 67,493 shares on 2/15/2023Ownership: 0.263%Virtu Financial LLCBought 66,182 shares on 2/15/2023Ownership: 0.258%Dimensional Fund Advisors LPSold 16,489 shares on 2/9/2023Ownership: 0.285%Simplex Trading LLCBought 12,000 shares on 2/2/2023Ownership: 0.000%View All Institutional Transactions NHWK Stock - Frequently Asked Questions Should I buy or sell NightHawk Biosciences stock right now? 0 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NightHawk Biosciences in the last twelve months. There are currently for the stock. The consensus among Wall Street research analysts is that investors should "n/a" NHWK shares. View NHWK analyst ratings or view top-rated stocks. What is NightHawk Biosciences' stock price forecast for 2023? 0 equities research analysts have issued twelve-month price targets for NightHawk Biosciences' shares. Their NHWK share price forecasts range from $10,000,000.00 to $0.00. On average, they expect the company's stock price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%. View analysts price targets for NHWK or view top-rated stocks among Wall Street analysts. How have NHWK shares performed in 2023? NightHawk Biosciences' stock was trading at $0.8051 at the beginning of the year. Since then, NHWK shares have increased by 11.8% and is now trading at $0.90. View the best growth stocks for 2023 here. When is NightHawk Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our NHWK earnings forecast. How were NightHawk Biosciences' earnings last quarter? NightHawk Biosciences, Inc. (NYSE:NHWK) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.01. The biopharmaceutical company earned $0.50 million during the quarter, compared to the consensus estimate of $0.57 million. NightHawk Biosciences had a negative trailing twelve-month return on equity of 45.24% and a negative net margin of 648.44%. When did NightHawk Biosciences' stock split? NightHawk Biosciences's stock reverse split on the morning of Friday, December 11th 2020. The 1-7 reverse split was announced on Thursday, December 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What is NightHawk Biosciences' stock symbol? NightHawk Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "NHWK." Who are NightHawk Biosciences' major shareholders? NightHawk Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (0.28%), Millennium Management LLC (0.26%), Virtu Financial LLC (0.26%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Edward B Smith III and John K A Prendergast. View institutional ownership trends. How do I buy shares of NightHawk Biosciences? Shares of NHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NightHawk Biosciences' stock price today? One share of NHWK stock can currently be purchased for approximately $0.90. How much money does NightHawk Biosciences make? NightHawk Biosciences (NYSE:NHWK) has a market capitalization of $23.09 million and generates $2.11 million in revenue each year. The biopharmaceutical company earns $-35,070,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. How can I contact NightHawk Biosciences? NightHawk Biosciences' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The official website for the company is www.nighthawkbio.com. The biopharmaceutical company can be reached via email at investorrelations@heatbio.com. This page (NYSE:NHWK) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.